Diagnosis
& Treatment

Find out if you have IC
and learn what treatment options
are available.

defeatic@imprimispharma.com Brought to you by

Receive updates from Defeat IC

Submit

Oral Medications

There is no known cure for interstitial cystitis, but oral medications have been around for many years providing patients access to relief of symptoms for pain, urgency, and frequency. According to the American Urological Association, oral medications are considered a second line treatment after self-management treatments such as adequate water intake, stress management, and diet modifications are unsuccessful.

Some oral medications can be expensive, and paying for certain medications may be stressful and burdensome for the patient. Being able to afford your oral medications can be stressful and may feel like a burden having to pay for high priced medications.

PPS-DR™* (Pentosan Polysulfate Sodium Delayed Release):

PPS-DR™ is a compounded formulation that may be prescribed by physicians for the treatment of interstitial cystitis. The compounded formulation is carefully prepared in delayed release capsules that allows for physicians to prescribe as little as twice daily dosing.

The compounded formulation is customized to an individual patient, and provides the added the convenience of twice daily dosing.

PPS-DR* compounded formulation is available for $99 per month. Click here to contact us for more information and we can provide you the information needed to bring to your physician.

Contact your doctor, or call us today at 844-FOR-MY-IC (844-367-6942) and we will help you find an IC Specialist.

Affordable

Cost effective to patients when other medications are not covered

Convenient

Delayed release capsules allow for as little as twice daily dosing

The Defeat IC™ educational campaign is brought to you by San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and customizable medicines to physicians and patients at accessible prices.

Follow us on